The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).

Brainstorm Cell Therapeutics is seeking FDA clearances to launch a Phase 3b clinical trial to test its NurOwn stem cell ...

Daily treatment with IPL344 for up to three years was safe and slowed ALS progression in a small Phase 2a clinical trial, ...

Neurosense Therapeutics’ PrimeC significantly reduces blood levels of miRNAs linked to amyotrophic lateral sclerosis, trial ...

Columnist Dagmar Munn explains how the use of a shoehorn not only helps her put on shoes, but also allows for some gentle ...

RAG-17 therapy slowed functional decline and stabilized or improved breathing in people with ALS who carry mutations in the SOD1 gene.